| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Bonneau C, Eliès A, Kieffer Y, et al. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer [J]. Breast Cancer Res, 2020, 22(1): 76.
|
| [3] |
Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722.
|
| [4] |
Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [J]. Ann Oncol, 2021, 32(10): 1216-1235.
|
| [5] |
Cardoso F, Van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer [J]. N Engl J Med, 2016, 375(8): 717-729.
|
| [6] |
Lænkholm AV, Jensen MB, Eriksen JO, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer [J]. J Clin Oncol, 2018, 36(8): 735-740.
|
| [7] |
Mishra A, Srivastava A, Pateriya A, et al. Metabolic reprograming confers tamoxifen resistance in breast cancer [J]. Chem Biol Interact, 2021, 347: 109 602.
|
| [8] |
Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years [J]. N Engl J Med, 2017, 377(19): 1836-1846.
|
| [9] |
Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer [J]. N Engl J Med, 2020, 383(26): 2557-2570.
|
| [10] |
Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial [J]. JAMA Oncol, 2020, 6(3): 367-374.
|
| [11] |
Piccart M, Van’T Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age [J]. Lancet Oncol, 2021, 22(4): 476-488.
|
| [12] |
Lee HB, Lee SB, Kim M, et al. Development and validation of a next-generation sequencing-based multigene assay to predict the prognosis of estrogen receptor-positive, HER2-negative breast cancer [J]. Clin Cancer Res, 2020, 26(24): 6513-6522.
|
| [13] |
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013 [J]. Ann Oncol, 2013, 24(9): 2206-2223.
|
| [14] |
Truong PT, Jones SO, Kader HA, et al. Patients with T1 to T2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy [J]. Int J Radiat Oncol Biol Phys, 2009, 73(2): 357-364.
|
| [15] |
Mcgale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8 135 women in 22 randomised trials [J]. Lancet, 2014, 383(9935): 2127-2135.
|
| [16] |
Smith BD, Smith GL, Haffty BG. Postmastectomy radiation and mortality in women with T1-2 node-positive breast cancer [J]. J Clin Oncol, 2005, 23(7): 1409-1419.
|
| [17] |
Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes [J]. Lancet, 2003, 361(9369): 1590-1596.
|
| [18] |
Pittman J, Huang E, Dressman H, et al. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes [J]. Proc Natl Acad Sci U S A, 2004, 101(22): 8431-8436.
|
| [19] |
Cheng SH, Horng CF, West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer [J]. J Clin Oncol, 2006, 24(28): 4594-4602.
|
| [20] |
Cheng SH, Tsai SY, Yu BL, et al. Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer [J]. Int J Radiat Oncol Biol Phys, 2013, 85(4): 953-958.
|
| [21] |
Cheng SH, Horng CF, Huang TT, et al. An eighteen-gene classifier predicts locoregional recurrence in post-mastectomy breast cancer patients [J]. EBioMedicine, 2016, 5: 74-81.
|
| [22] |
Kao KJ, Chang KM, Hsu HC, et al. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization [J]. BMC Cancer, 2011, 11: 143.
|
| [23] |
Cheng SH, Huang TT, Cheng YH, et al. Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer [J]. PLoS One, 2017, 12(9): e0184372.
|
| [24] |
Huang TT, Chen AC, Lu TP, et al. Clinical-genomic models of node-positive breast cancer: training, testing, and validation [J]. Int J Radiat Oncol Biol Phy, 2019, 105(3): 637-648.
|
| [25] |
Lei L, Wang XJ, Mo YY, et al. DGM-CM6: a new model to predict distant recurrence risk in operable endocrine-responsive breast cancer [J]. Front Oncol, 2020, 10: 783.
|
| [26] |
Zhang L, Zhou M, Liu Y, et al. Is it beneficial for patients with pT1-2N1M0 breast cancer to receive postmastectomy radiotherapy? An analysis based on RecurIndex assay [J]. Int J Cancer, 2021, 149(10): 1801-1808.
|
| [27] |
Krop I, Ismaila N, Stearns V. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice focused update guideline summary [J]. J Oncol Pract, 2017, 13(11): 763-766.
|
| [28] |
中华人民共和国国家卫生健康委员会. 乳腺癌诊疗指南(2022年版)[J]. 中国合理用药探索，2022, 19(10): 1-26.
|
| [29] |
Yeo W, Ueno T, Lin CH, et al. Treating HR+/HER-2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 consensus and position on ovarian suppression [J]. Breast Cancer Res Treat, 2019, 177(3): 549-559.
|
| [30] |
Kwon MJ, Lee JE, Jeong J, et al. Comparison of genes well BCT score with Oncotype DX recurrence score for risk classification in Asian women with hormone receptor-positive, HER-2-negative early breast cancer [J]. Front Oncol, 2019, 9: 667.
|
| [31] |
Chang CH, Yang PS, Hsieh CM, et al. Prognostic comparison between Oncotype DX® and a 23-gene classifier, RecurIndex®，on the Taiwan breast cancer population [J]. Diagnostics (Basel), 2022, 12(11)：285.
|
| [32] |
Yang PS, Lee YH, Chung CF, et al. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and Oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer [J]. Jpn J Clin Oncol, 2019, 49(11): 1029-1036.
|
| [33] |
Toi M, Iwata H, Yamanaka T, et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population [J]. Cancer, 2010, 116(13): 3112-3118.
|
| [34] |
Wang H, Ma L, Zhang Y, et al. RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients [J]. Front Oncol, 2022, 12: 896 431.
|
| [35] |
Pennarun N, Chiu JY, Chang HC, et al. Cost-effectiveness analysis from a societal perspective of recurrence index for distant recurrence (RecurIndex) in women with hormone receptor-positive and HER2-negative early-stage breast cancer [J]. Cancer Manag Res, 2022, 14: 761-773.
|
| [36] |
Wang SY, Chen T, Dang W, et al. Incorporating tumor characteristics to maximize 21-gene assay utility: a cost-effectiveness analysis [J]. J Natl Compr Canc Netw, 2019, 17(1): 39-46.
|
| [37] |
Zhang S, Liu B, Zhou M, et al. The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients [J]. Sci Rep, 2021, 11(1): 7657.
|
| [38] |
Sella T, Gelber SI, Poorvu PD, et al. Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score test in young women with estrogen receptor-positive early breast cancer [J]. Breast Cancer Res Treat, 2021, 186(1): 157-165.
|
| [39] |
Soliman H, Wagner S, Flake DD 2nd, et al. Evaluation of the 12-gene molecular score and the 21-gene recurrence score as predictors of response to neo-adjuvant chemotherapy in estrogen receptor-positive, HER2-negative breast cancer [J]. Ann Surg Oncol, 2020, 27(3): 765-771.
|
| [40] |
Dubsky PC, Singer CF, Egle D, et al. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial [J]. Eur J Cancer, 2020, 134: 99-106.
|
| [41] |
中国抗癌协会国际医疗与交流分会，中国医师协会肿瘤医师分会乳腺癌学组. 激素受体阳性人表皮生长因子受体2阴性早期乳腺癌术后辅助治疗多基因检测应用专家共识 [J]. 中华肿瘤杂志，2022, 44(1): 54-59.
|